NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,379.58 +172.45 (+0.95%) CRUDE OIL
79.07 +0.12 (+0.15%) GOLD FUTURES
2,310.20 +0.60 (+0.03%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,454.41 +1,711.24 (+3.74%)
STTK May 2024 7.500 call
| Previous close | 4.1000 |
| Open | 4.1000 |
| Bid | 3.3000 |
| Ask | 4.0000 |
| Strike | 7.50 |
| Expiry date | 2024-05-17 |
| Day's range | 4.1000 - 4.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 25 |
ZacksShattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates
Shattuck Labs (STTK) delivered earnings and revenue surprises of 21.28% and 457.50%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireShattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 Annual Meeting in June – - Randomized, controlled Phase 1B dose-expansion cohort in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) patients expected to initiate enrollment in the second quarter of 2024 – - Presented preclinical data at the 2024 A
Simply Wall St.Owning 36% shares,institutional owners seem interested in Shattuck Labs, Inc. (NASDAQ:STTK),
Key Insights Significantly high institutional ownership implies Shattuck Labs' stock price is sensitive to their...
